N/A
N=90
Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Bottom Line
View on ClinicalTrials.gov: NCT01015625 ↗Enrolled (actual)
90
Serious AEs
—
Results posted
Aug 2024
Primary outcome: Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Surgery (Procedure); Surgery on Demand (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Primary completion
- Jul 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival (OS) |
34.6; 56.2 | 0.042 sig |
| SECONDARY Time to Distant Progression |
13.7; 24.4 | 0.147 |
| SECONDARY Time to Local Progression (TTPl) |
59.4; 55.8 | 0.890 |
Summary
Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy
Eligibility Criteria
Inclusion Criteria
- Patients age ≥ 18 years
- Eastern Cooperative Oncology Group Performance Status is 0 -2
- Untreated synchronous metastasized invasive carcinoma of the breast with the primary tumor in situ (bilateral synchronous metastasized breast cancer patients are eligible)
- The primary tumor must be identified and may be any size, however, primary resection with resection free margins must be possible
- Invasive adenocarcinoma of the breast on histological examination
- The metastatic site must be identified by radiological assessment(Computer Tomography of the chest and the abdomen OR ultrasound and chest x ray for visceral metastases; bone scan AND/OR computer tomography AND/OR magnetic resonance for bone metastases). A biopsy is not necessary.
- Written informed consent must be obtained and documented prior to beginning any protocol specific procedures and according to local regulatory requirements
- able to comply with the protocol requirements during the treatment and follow-up period.
Exclusion Criteria
- Patients in whom a R0 resection (microscopic free margins) is clinically questionable
- Inflammatory cancer
- Patients with a brain metastasis
- Patients who are not eligible for general anesthesia and operations
- Patients without metastatic breast cancer (patients with a tumor marker value (CEA, CA15-3) above normal levels without the radiological proven evidence of metastases are not eligible for the study)
- Patients with a second untreated malignancy
- Any previous malignancy treated with curative intent and the patient has not been disease-free for 5 years - exceptions are: (a)carcinoma in situ of the cervix, (b)squamous carcinoma of the skin, (c)basal cell carcinoma of the skin
- Patients with any recurrent cancer disease
- Pregnant or lactating women
- Patients are not allowed to be part of another local therapy trial
Data sourced from ClinicalTrials.gov (NCT01015625). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.